Experimental CAR-T therapy takes aim at tough blood cancers
NCT ID NCT07200479
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will test a new immune cell therapy called CT1194D CAR-T in 20 adults with relapsed or refractory B-cell cancers (lymphoma or leukemia). The main goals are to check safety, find the right dose, and see how long the cells last in the body. Researchers will also track whether the cancer shrinks or disappears, but this is a small, first-in-human study focused on safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CT1194D CAR-T cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could point toward a new treatment option for patients with hard-to-treat B-cell cancers that have not responded to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 20 participants, so the main goal is safety, not proof of effectiveness. CAR-T therapy can cause severe side effects like cytokine release syndrome, and the cancer may still return.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- What happens years after CAR-T therapy? a study aims to find out
- Can a single shot build a cancer army inside the body?